title: Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
authors.affiliation: Department of Public Health and Epidemiology, University of Birmingham, UK.
authors.forename: C
authors.initials: C
authors.lastname: Hyde
authors.forename: B
authors.initials: B
authors.lastname: Wake
authors.forename: S
authors.initials: S
authors.lastname: Bryan
authors.forename: P
authors.initials: P
authors.lastname: Barton
authors.forename: A
authors.initials: A
authors.lastname: Fry-Smith
authors.forename: C
authors.initials: C
authors.lastname: Davenport
authors.forename: F
authors.initials: F
authors.lastname: Song
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D019008:Drug Resistance, Neoplasm; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014740:Vidarabine; C024352:fludarabine